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Summary
Red cell alloantigen exposure can cause alloantibody-associated morbidity.
Murine models have suggested that inflammation modulates red cell
alloimmunisation. This study quantifies alloimmunisation risks during
infectious episodes in humans. We performed a multicentre case–control
study within a source population of patients receiving their first and subse-
quent red cell transfusions during an 8-year follow-up period. Patients
developing a first transfusion-induced red cell alloantibody (N = 505) were
each compared with two similarly exposed, but non-alloimmunised con-
trols (N = 1010) during a 5-week ‘alloimmunisation risk period’ using
multivariate logistic regression analysis. Transfusions during ‘severe’ bacte-
rial (tissue-invasive) infections were associated with increased risks of
alloantibody development [adjusted relative risk (RR) 134, 95% confidence
interval (95% CI) 097–185], especially when these infections were accom-
panied with long-standing fever (RR 306, 95% CI 157–596). Dissemi-
nated viral disorders demonstrated a trend towards increased risks
(RR 241, 95% CI 089–653), in apparent contrast to a possible protection
associated with Gram-negative bacteraemia (RR 058, 95% CI 013–114).
‘Simple’ bacterial infections, Gram-positive bacteraemia, fungal infections,
maximum C-reactive protein values and leucocytosis were not associated
with red cell alloimmunisation. These findings are consistent with murine
models. Confirmatory research is needed before patients likely to develop
alloantibodies may be identified based on their infectious conditions at
time of transfusion.
Keywords: red blood cell alloimmunisation, blood transfusion, infections,
inflammation, humans.
Red cell alloimmunisation challenges the provision of com-
patible donor blood and, most importantly, might induce
severe haemolytic transfusion reactions (Serious Hazards Of
Transfusion [SHOT], 2014; Transfusion and Transplantation
Reactions In Patients [TRIP], 2014). Consequently, some
selected patients receive extensively matched blood (Dutch
Institute for Healthcare Improvement [CBO], 2011; United
Kingdom Blood Services, 2013). Despite the effectiveness of
these risk-based matching practices (Vichinsky et al, 2001;
Lasalle-Williams et al, 2011; Schonewille et al, 2015), non-
selected patients do experience alloimmunisation-mediated
complications (Harvey et al, 2014; TRIP, 2014; SHOT, 2015)
warranting consideration of additional risk factors.
In addition to the chance of encountering a high
immunogenic non-self antigen (Evers et al, 2016), clinical
conditions affecting the recipient’s immune response
research paper
First published online 18 August 2016
doi: 10.1111/bjh.14307
ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 175, 956–966
probably modulate alloimmunisation. Identification of such
factors might enable allocating extensively matched blood
principally to high-risk patients.
Experimentally induced inflammation has consistently
been demonstrated as a major determinant of red cell alloim-
munisation in mice (Hendrickson et al, 2006, 2007; Hen-
drickson, 2008; Smith et al, 2012). In line with this, pro-
inflammatory conditions related to sickle cell disease as well
as febrile reactions to donor platelets were shown to enhance
alloimmunisation in humans (Yazer et al, 2009; Fasano et al,
2015). Apart from one case report (Hata et al, 2013) to the
best of our knowledge, the influence of infection-associated
inflammation on red cell alloimmunisation in humans has
not been reported.
In this nested case–control study, we quantified relative
alloimmunisation risks for patients receiving red cell units dur-
ing an infectious episode, according to the type of infection, its
intensity, and the patient’s inflammatory response to it.
Patients and methods
Study design and setting
We performed a nested case–control study within a source
population of previously non-transfused and non-alloimmu-
nised patients in three university hospitals and three refer-
ence hospitals in the Netherlands. Using this design, we
compared patients who developed red cell alloantibodies fol-
lowing transfusion with non-alloimmunised controls on the
basis of supposed causal attributes, including various types of
infections. Details on the source population, including its eli-
gibility criteria, and our case–control study design have been
previously published (Zalpuri et al, 2012a; Evers et al, 2016).
To summarize, patients were eligible if they received their
first red cell transfusion during the study period in one of
the participating hospitals, provided this transfusion was pre-
ceded by a negative antibody screen and followed by an anti-
body screen, hereby permitting evaluation of alloantibody
development. The study period per hospital depended on
electronic availability of the necessary data between 1 January
2005 and 31 December 2013 (for details, see Data S1). All
red cell units were prepared by buffy-coat depletion of whole
blood donations, subsequently filtered through a leucocyte
depletion filter, and stored in saline, adenine, glucose, and
mannitol (SAGM) for a maximum of 35 days (CBO, 2011).
A patient was defined as a case upon developing a first,
transfusion-induced red cell alloantibody directed against one
of the following antigens: c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb,
Lua, Lub, M, N, S or s. Anti-D immunised patients were not
taken into consideration because we were unable to discrimi-
nate whether anti-D was caused by unmatched transfusions,
or (mainly regarding fertile women) was due to recent anti-D
administration in the context of a D-positive pregnancy or
transfusion. Patients who formed antibodies, yet either lacked
exposure to a (documented or assumed) antigen-positive red
cell unit or expressed the antigen themselves (i.e. auto-immu-
nised patients) were deemed ineligible. In addition, alloimmu-
nised patients were excluded if their first-time alloantibody
positive screen occurred within 7 days of the first mismatched
transfusion, as these were more likely to represent boosting of
earlier primary immunisations. By consulting the nationwide
alloimmunisation registry
(http://www.sanquin.nl/producten-diensten/diagnostiek/trix),
we additionally excluded patients previously diagnosed with
alloimmunisation in other hospitals. Considering the above-
mentioned criteria, we specifically aimed to exclude previously
alloimmunised patients, including pregnancy-induced immu-
nisations in women. Finally, haemoglobinopathy patients and
infants below 6 months of age were not included.
Each eligible case was matched to two randomly selected
non-alloimmunised control patients based on the hospital
and on the (lifetime) number of red cell transfusions
received at the time of alloimmunisation. This ‘incidence-
density sampling strategy’ ensured that controls were exposed
to at least the same amount of transfusions as their matched
cases and thus formed a representative sample of the source
population (Rothman, 2007).
For all cases, we assumed that the last antigen-mismatched
transfusion (the ‘Nth’ or implicated transfusion) preceding the
first positive screen most likely elicited alloimmunisation. If
this last mismatched transfusion could not be identified due
to incomplete typing of donor units, we assumed the last non-
tested unit preceding the first positive screen by at least 7 days
to have elicited alloimmunisation. An ‘alloimmunisation risk
period’ was then constructed, stretching from 30 days before
up to 7 days after this implicated Nth transfusion. A similar
risk period around the Nth transfusion was determined for the
matched controls. The implicated transfusion and its alloim-
munisation risk period are illustrated in Fig 1.
For all cases and controls, we recorded various clinical
conditions during the alloimmunisation risk period.
The study protocol was approved by the Ethical Review
Board at the Leiden University Medical Centre in Leiden and
by the local board of each participating centre.
First-formed red cell alloantibodies
Patients in the Netherlands are routinely screened for red cell
alloantibodies at a maximum of 72 h prior to red cell trans-
fusion. According to the Dutch transfusion guideline (CBO,
2011), commercially available 3-cell screening panels are
required to be homozygous positive for D, C, c, E, e, K, Fya,
Fyb, Jka, Jkb, M, S and s. The presence of the K antigen in its
heterozygous form is a minimum requirement. The presence
of Cw, Lua, Wra, and Kpa is not mandatory on commercially
available screening cells (CBO, 2011). Antibody screening
involves a three-cell panel using an indirect antiglobulin test
[column agglutination technology from either BioRad (Cres-
sier, Switzerland), or Ortho Clinical Diagnostics (Raritan, NJ,
USA)]. If positive, screening is followed by subsequent
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antibody identification by an 11-cell panel using the same
technique.
Data acquisition
We gathered routinely stored data on red cell transfusion
dates, dates and results of antibody screens (including anti-
body specificity), patients’ date of birth, sex and leucocyte
counts from the hospitals’ electronic laboratory information
systems. In addition, we examined the medical charts of all
cases and controls for the presence of various potential clini-
cal risk variables during the alloimmunisation risk period,
including dates of infection, the causative microorganisms,
dates of fever (temperature ≥385°C), leucocyte counts, and
C-reactive protein (CRP) values.
Bacterial infections comprised tissue-invasive infections
(i.e. involving an anatomic site location) and bacteraemia
(i.e. involving positive blood cultures).
Tissue-invasive bacterial infections were considered present
when confirmed by either a positive blood or tissue culture,
or when a suspected clinical infectious phenotype was sup-
ported by an overtly disease-specific radiographic anomaly
e.g. a clear lobar consolidation on a chest x-ray in a patient
with fever and cough. We categorized these infections into
‘mild’ or ‘severe’ according to their expected degree of sys-
temic inflammation. Mild tissue-invasive bacterial infections
included: routine (tip) cultures from central catheters, cathe-
ter-induced phlebitis, lower urinary tract infections, bacterial
enteritis, skin and superficial wound infections, and upper
respiratory tract infections. ‘Severe’ tissue-invasive bacterial
infections included: abscesses, intra-abdominal infections
including spontaneously or secondarily infected abdominal
fluid collections, arthritis, bursitis, myositis, fasciitis, infected
haematoma, bacterial meningitis, deep wound or skin
infections, endocarditis, mediastinitis, pericarditis, infected
foreign material, lower respiratory tract infections,
osteomyelitis, spondylodiscitis and upper urinary tract infec-
tions.
Bacteraemia were categorized according to their Gram-
positive or Gram-negative causative microorganism.
For the qualification of a viral infection, a positive poly-
merase chain reaction (PCR) test demonstrating the replica-
tion of viral RNA or DNA was needed or, in case a PCR test
was not performed, the clinical condition needed to be
clearly virally induced, e.g. herpes labialis. Viraemia and dis-
seminated viral zoster infections were defined as ‘dissemi-
nated viral infections’, in contrast to ‘local viral infections’,
which were restricted to one anatomic site location.
Statistical analyses
The associations of various infections with the development
of red cell alloimmunisation were evaluated using logistic
regression analyses. For crude relative risk (RR) calculations,
we conditioned on the matched variables, i.e. hospital and
cumulative number of red cell units received.
For multivariate analyses, we also conditioned on mea-
sured confounders, taking into account that a confounder
meets the prerequisites of being associated with the exposure
(i.e. infections) in the source population, is (a marker for) a
causal risk factor of the outcome (i.e. alloimmunisation) and
is not in the causal pathway between the exposure and the
outcome (Hernan et al, 2002; Middelburg et al, 2014).
Consequently, we used the following strategy. First, we iden-
tified a subset of covariates to be confounders of a given
determinant based on their observed association with the
determinant within the source population (i.e. the non-
alloimmunised controls). Such an association was defined as
(last) Negative screen
K+
First serological 
anti-K detection
‘Lag period’
7 days
Alloimmunisation risk period
Control
Case
Fig 1. The implicated transfusion and alloimmunisation risk period. The last antigen-mismatched transfusion preceding the first serological
detection of an antibody was defined as the ‘implicated (or Nth) transfusion’ since this transfusion was the most likely to influenc alloimmunisa-
tion. To exclude possible boosting events, this implicated transfusion was required to precede the first positive screen by at least 7 days (i.e. lag
period). An alloimmunisation risk period was then constructed starting 30 days before and finishing 7 days after this implicated transfusion. Con-
trols received at least the same number of red cell units as their matched case. A similar alloimmunisation risk period around the Nth matched
transfusion was constructed.
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a ≥3% difference in covariate presence between controls
exposed and controls not exposed to the determinant.
Covariates in the causal pathway between the determinant
and the outcome were not considered as confounders (Her-
nan et al, 2002). Second, to be able to accurately control for
confounders with low prevalences, we estimated a probability
score for each determinant using logistic regression with the
potential confounders as predictors (Brookhart et al, 2013).
Third, to minimize bias due to missing data on the con-
founders, we used multiple imputation. Details on the used
imputation model can be found in the Data S1 and Table SI.
Finally, we evaluated the association between various types of
infections and red cell alloimmunisation by subsequently
entering the corresponding probability scores into the logistic
regression model with alloimmunisation as the outcome and
conditioning on the matched variables.
We next assessed the association of level of CRP values
and leucocytosis as possible markers of inflammation with
red cell alloimmunisation. Leucocytosis was categorized as
maximum measured leucocyte counts of 10–15, 15–20, 20–30
and >30 9 109/l, and referenced to normal counts
(4–10 9 109/l). Maximum measured CRP values were cate-
gorized as 30–100, 100–200, 200–300 and >300 mg/l, and
referenced to values ≤30 mg/l. Missing CRP and leucocyte
values were multiply imputed using the same strategy as
described above. While the likelihood that an increased
inflammatory parameter has been recorded at least once
increases with the number of measurements and thus with
the duration of hospitalization, we repeated these analyses
limited to parameters measured within the week following
the implicated transfusion. As elevated CRP levels and leuco-
cytosis reflect various clinical conditions preventing causal
inferences, they are presented here only as unadjusted RRs.
As anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M
can also form ‘naturally’ (e.g. directly in response to microbial
epitope exposure (Reid et al, 2004), we evaluated a possible
association between the presence of these antibodies and vari-
ous types of infections using Pearson’s chi-square test. P-
values <005 were considered to be statistically significant.
As we used an incidence-density sampling procedure to
select controls (Rothman, 2007), we interpreted and present
all odds ratios as RRs with 95% confidence intervals (95% CI).
Sensitivity analyses
For some patients, the presence or absence of a certain type
of infection could not be determined. These patients were
left out of the corresponding analysis. Regarding severe bac-
terial infections, we performed a sensitivity analysis in which
these patients were alternately assigned to exposure and non-
exposure of this infection.
For patients with a suspected lower respiratory infection
without conclusive or available cultures, we considered this
infection to be due to a bacterial microorganism. Although
viral or (rarely) fungal pathogens may cause pneumonia,
bacterial microorganisms are the most common cause in
Dutch hospitalised patients, with Streptococcus Pneumoniae
and Haemophilus Influenzae alone representing 30–75% of
causative pathogens (Wiersinga et al, 2012).
Finally, as contaminated blood cultures positive for coagu-
lase-negative staphylococci (CNS) might dilute an existing
effect of Gram-positive bacteraemia, we compared RRs for
all Gram-positive bacteraemia with those for non-CNS
Gram-positive bacteraemia.
Results
Among 54 347 newly-transfused patients, 24 063 were con-
sidered eligible (Fig S1) of which 505 patients (21%) formed
red-cell alloantibodies. Thirty-seven of these alloimmunised
patients (73%) only received units of which the cognate
antigen was unknown. For these, we assumed the last non-
tested unit preceding the first positive screen to have elicited
alloimmunisation.
General and clinical characteristics of the 505 cases and
their 1010 matched controls during the alloimmunisation
risk period are presented in Table I.
Infections during the alloimmunisation risk period
Among all cases and controls, 473 patients were diagnosed
with at least one infection during the alloimmunisation risk
period. Of these, 417 suffered from bacterial infections, 53
from viral infections and 56 from fungal infections (Table II).
For 222 of 269 patients (825%) diagnosed with a severe
tissue-invasive bacterial infection, the causal microorganism
was identified by culture. For three of 53 virally-infected
patients, no PCR test was performed during the alloimmuni-
sation risk period. These patients were nevertheless included
based on their clinical condition: one patient receiving an
allogeneic stem cell transplantation with an outbreak of vari-
cella zoster, one patient receiving chemotherapy for Burkitt
lymphoma with herpes labialis, and one patient with liver
cirrhosis due to a chronic hepatitis C infection.
Identified confounders per alloimmunisation determinant
are presented in Tables SII and SIII. As illustrated, control
subjects with viral infections were younger, had received
more red cell units, and were more often leucopenic as com-
pared to those without viral infections. These differences
were probably due to a higher frequency of haematological
malignancies and associated treatment modalities.
Missing data for any identified confounder per determinant
was at a maximum of 31%. CRP values were not measured in
343 patients (226%) during the risk period (Table SI).
The association between various types of infections and
red cell alloimmunisation
The number of cases and controls diagnosed per type of
infection are presented in Table III. For some patients, the
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presence or absence of a certain type of infection could not
be determined. The majority of these cases were due to an
unestablished origin of the inflammatory condition (i.e. an
infection or other inflammatory causes). In order to avoid
misclassification, we omitted these patients from the corre-
sponding analysis.
Mild bacterial infections were not associated with alloim-
munisation. Patients with a severe tissue-invasive bacterial
infection tended towards increased alloimmunisation risks
[adjusted RR 134 (95% CI 097–185); Table III]. Relative
risks increased to significance when these infections were
accompanied with long-lasting fever [adjusted RR 306 (95%
CI 157–596) with fever present for at least 7 days, Table IV].
The timing of fever i.e. occurring close to the implicated
transfusion or at any time point during the risk period did
not influence RRs (Table SIV). A sensitivity analysis on
patients originally omitted from the analysis on severe bacte-
rial infection (N = 47) did not change RRs (Table SV).
Given that alloantibodies against E, Cw, Lea, Leb, Lua, and
M can also form ‘naturally’, [e.g. in response to microbial
epitope exposure rather than to transfusion-related red cell
exposure (Reid et al, 2004)] we evaluated a possible
Table I. Patient characteristics during the alloimmunisation risk period.
Characteristics Cases (N = 505)
Controls
(N = 1010)
Missing
data
Male 237 (469) 568 (562)
Age, years (median, IQR) 670 (550–759) 653 (516–751)
Transfused in a university hospital 232 (459) 464 (459)
Cumulative (lifetime) number of red cell units up to implicated transfusion, median (IQR) 4 (2–8) 4 (2–8)
Single transfused, N (%) 26 (51) 7 (07)
Follow-up (days) up till last screen, median (IQR) 92 (20–193) 117 (10–609)
Cumulative number of red cell units during risk period, median (IQR) 3 (2–6) 4 (2–8)
Days transfused during risk period, median, (IQR) 1 (1–3) 2 (1–3)
ICU admission 177 (365) 369 (350)
Days at ICU, median (IQR) 7 (2–18) 7 (2–17) 4
Surgery 267 (529) 457 (452) 2
Thoracic including CABG 61 (121) 144 (143)
Abdominal 100 (198) 181 (179)
Back or spinal cord 3 (06) 11 (11)
Diabetes mellitus type 1 6 (12) 7 (07)
Diabetes mellitus type 2 91 (180) 176 (174) 1
Atherosclerosis* 198 (395) 314 (315) 17
Chronic obstructive airway disease† 43 (85) 89 (90) 20
Splenectomy (in past or during risk period) 1 (02) 19 (19)
Organ transplant 4 (08) 23 (23)
Liver cirrhosis 13 (26) 24 (24) 2
Haematological malignancy 60 (119) 210 (208) 13
Carcinoma 112 (223) 183 (182) 7
Chemotherapy 66 (131) 219 (218) 6
Radiotherapy 15 (30) 37 (36)
Leucopenia‡ 102 (202) 313 (310) 41
Haematopoietic stem cell transplantation (autologous or allogeneic, in past or during risk period) 10 (20) 63 (62)
Graft versus host disease (acute or chronic) 4 (15) 15 (08) 3
Immunosuppressant medication§ 154 (309) 423 (424) 20
GFR ≤ 30 ml/min¶ 56 (111) 149 (148) 2
Dialysis (either chronic or acute)k 31 (61) 98 (97)
Values are n (%), unless otherwise stated. Numbers of patients for whom data on certain diagnoses and/or treatment modalities were not docu-
mented are presented as missing.
CABG, coronary artery bypass graft; GFR, glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range.
*Systemic or coronary atherosclerosis.
†Chronic asthma bronchiale or chronic obstructive pulmonary disease.
‡At least one measured leucocyte count below lower limit of normal.
§Medication under subcategory H02 (corticosteroids) or L04 (other immunosuppressants) within the Anatomical Therapeutic Chemical (ATC)
classification index (WHO Collaborating Centre for Drug Statistics Methodology, 2016).
¶GFR below 30 ml/min during at least 1 week of the risk period (with GFR calculated using the Modification of Diet in Renal Diseases [MDRD]
equation; Levey et al, 1999).
kHaemodialysis, peritoneal dialysis, or continuous veno-venous haemofiltration needed for at least 1 day during the risk period.
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association between the induction of these antibodies and
various infections using Pearson’s chi-square test. The distri-
bution of alloantibodies known to also occur ‘naturally’ did
not differ between patients with and without severe bacterial
infections (Table V).
Interestingly, patients with a Gram-negative bacteraemia
tended to demonstrate reduced alloimmunisation rates [ad-
justed RR 058 (95% CI 013–114)], while Gram-positive
bacteraemia was not associated with red cell alloimmunisa-
tion (Table III). To exclude a potential dilution of
Table II. Infections diagnosed during the alloimmunisation risk period.
(a) Locus of bacterial infections according to severity
Mild bacterial infections N Severe bacterial infections N
Diagnosed in no. of patients 116 Diagnosed in no. of patients 269
Bacterial enteritis 12 Abdominal infections (including abscesses) 87
Catheter related* 37 Arthritis, bursitis, myositis, fasciitis, infected haematoma 11
Lower urinary tract infection 36 Bacterial meningitis 5
Skin and superficial wound infections 25 Deep wound or skin infection 20
Upper respiratory tract infection 11 Endocarditis, mediastinitis, pericarditis 21
Infected foreign material 15
Lower respiratory tract infection 85
Non-abdominal abscesses 17
Osteomyelitis, spondylodiscitis 5
Upper urinary tract infection 19
(b) Microorganism genus (and species)
Gram-positive bacteraemia N Gram-negative bacteraemia N
Diagnosed in no. of patients 117 Diagnosed in no. of patients 57
Bacillus 1 Bacteroides 4
Clostridium 1 Burkholdera 1
Corynebacterium 2 Capnocytophaga 1
Enterococcus 30 Enterobacter 8
Gemella 2 Escheria (Coli) 23
Listeria 1 Neisseria (Meningitides) 1
Micrococcus 1 Klebsiella 11
Staphylococcus 62 Proteus 2
Excluding coagulase negative 22 Pseudomonas 9
Streptococcus 25 Serratia 7
Stenotrophomonas 1
Viral infections Fungal infections
Diagnosed in no. of patients 53 Diagnosed in no. of patients 56
Local viral infections Aspergillus (pulmonary) 11
BK (cystitis) 1 Candida 42
HSV (stomatitis) 13 Stomatitis 10
Respiratory virus† 11 Candidaemia 11
Enteral virus‡ 2 Other location 22
Disseminated viral diseases Pneumocystis (jirovecii) 2
Adenoviraemia 3 Penicillium (pulmonary) 1
BK viraemia 1
Cytomegalovirus viraemia 11
Epstein Barr Virus viraemia 2
Hepatitis C vireamia 6
Human Herpesvirus- 6 viraemia 2
Human immunodeficiency virus 3
Varicella Zoster Virus reactivation 3
Cumulative numbers per type of infection do not necessarily equal the number of patients diagnosed with this infection, as individual patients
can have been infected with multiple microorganisms and types of infections.
*Routine (tip) cultures from central catheters and catheter induced phlebitis.
†Coronavirus (1), H1N1 virus (1), herpes simplex virus- 1 with bronchial location (1), influenza-virus (2), para-influenza virus (2), respiratory
syncytial virus (1), rhinovirus (3).
‡Norovirus (1), rotavirus (1).
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an existing effect by contaminated blood cultures positive
for CNS, we also evaluated the association of non-CNS
Gram-positive bacteraemia with alloimmunisation. RRs
from this analysis were identical to the originally calculated
RRs.
Any viral disease tended to be associated with increased
red cell alloimmunisation incidences. The adjusted RR asso-
ciated with disseminated viral infections was 241 (95% CI
089–653). The presence of fever did not influence RRs of
viral infections (Table IV).
Table III. Association between (various types of) bacterial and viral infections and red cell alloimmunisation.
Type of infection
Cases,
N/total
Controls,
N/total RR (95% CI)*
Adjusted RR
(95% CI)†
Excluded
from analysis
Bacterial infections
Tissue invasive infections 129/486 228/961 117 (090–151) 130 (098–174) 68
Mild 39/499 77/989 099 (066–149) 108 (070–166) 27
Severe 100/490 169/978 122 (092–162) 134 (097–185) 47
Bacteraemia 45/502 114/1003 075 (051–109) 089 (059–136) 10
Gram-positive 34/502 83/1003 078 (051–120) 108 (066–174) 10
Gram-positive, non-CNS 24/504 61/1009 082 (040–167) 096 (056–165) 2
Gram-negative 13/505 44/1010 057 (030–109) 058 (013–114) 0
Viral infections
All 15/503 38/1003 072 (038–138) 156 (075–325) 9
Local 7/503 20/1003 071 (029–174) 180 (065–498) 9
Disseminated 10/505 20/1010 089 (040–202) 241 (089–653) 0
Fungal infections
All 12/501 44/1001 050 (025–099) 060 (029–125) 13
Candidaemia 4/505 7/1010 119 (031–455) 293 (054–1589) 0
Invasive aspergillus 1/503 10/1004 017 (002–142) 033 (003–328) 8
Patients for whom the presence or absence of a given infection could not be determined were excluded from the corresponding analysis.
RR, relative risk; 95% CI, 95% confidence interval; CNS, coagulase negative staphylococcus.
*Adjusted for: number of transfused red cell units and hospital.
†Additionally adjusted for identified potential confounders (for details, see Table SIII).
Table IV. Infections and red cell alloimmunisation according to the presence of fever and its duration.
Type of infection Fever Cases, N/total Controls, N/total RR (95% CI)* Adjusted RR (95% CI)†
Severe bacterial infection
 390/490 809/978 ref. ref.
+ – 17/490 48/978 072 (041–129) 079 (044–143)
+ 1–6 days 59/490 101/978 120 (084–171) 133 (091–199)
+ ≥7 days 24/490 20/978 267 (140–507) 306 (157–596)
Gram-positive bacteraemia
 468/502 921/1003 ref. ref.
+ – 3/502 13/1003 051 (015–181) 088 (024–328)
+ 1–6 days 21/502 54/1003 072 (042–122) 092 (052–161)
+ ≥7 days 10/502 15/1003 129 (055–303) 214 (084–541)
Gram-negative bacteraemia
 492/505 966/1010 ref. ref.
+ – 0/505 6/1010 0 (NC) 0 (NC)
+ 1–6 days 12/505 34/1010 070 (035–139) 071 (035–145)
+ ≥7 days 1/505 4/1010 052 (004–630) 053 (004–662)
Disseminated viral diseases
 495/505 990/1010 ref. ref.
+ – 4/505 7/1010 114 (033–397) 189 (050–715)
+ 1–6 days 4/505 9/1010 061 (016–238) 377 (064–2224)
+ ≥7 days 2/505 4/1010 112 (020–639) 258 (037–17. .82)
Only numbers of patients for whom the presence or absence of a given infection could be determined are presented.
RR, relative risk; 95% CI, 95% confidence interval; NC, not computable.
*Adjusted for: number of transfused red cell units and hospital.
†Additionally adjusted for identified potential confounders (for details, see Table SIII).
D. Evers et al
962 ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 175, 956–966
Fungal infections, as well as candidaemia and invasive
aspergillus infections separately, were associated with hetero-
geneous RRs not reaching significance (Table III).
The association between laboratory indicators of
inflammation and red cell alloimmunisation
Neither leucocytosis nor CRP level was associated with red
cell alloimmunisation. A sensitivity analysis on parameters
determined within the week following the implicated transfu-
sion did not change these results (Table SVI).
Discussion
This study, the first of its kind, in transfused patients sug-
gests a possible association between infectious conditions and
red cell alloimmunisation. Specifically, our observations sug-
gest alloimmunisation to be influenced by the type and
intensity of, and the patient’s inflammatory response to
infections. In summary, severe (tissue-invasive) bacterial and
viral infections were associated with increased incidences of
alloimmunisation [RRs 134 (95% CI 097–185) and 241
(95% CI 089–653)]. In contrast, Gram-negative bacteraemia
coincided with a twofold reduction of alloimmunisation risk
[RR 058 (95% CI 013–114)].
Our findings certainly require additional confirmatory
research. However, they seem to be biologically plausible and
are in line with prior animal experiment observations (Hen-
drickson et al, 2006, 2007, 2008; Smith et al, 2012).
First, long-lasting fever with severe bacterial infections was
associated with a substantially increased risk [RR 306 (95%
CI 157–596)]. Here, persistence of fever could have
reflected the most severe bacterial infections inducing a pro-
found inflammatory response. Alternatively, or additionally,
fever might have been due to other concomitant inflamma-
tory conditions. Yet, both explanations are consistent with
the ‘danger model’ (Matzinger, 1994) which postulates that
an immune response is facilitated by pathogen-associated
molecular patterns or structures released from cells undergo-
ing stress (Matzinger, 1994; Gallucci & Matzinger, 2001;
Kawai & Akira, 2010).
Second, although the 95% CI encompassing 1 (i.e. a null
effect) warrants firm conclusions, we observed substantially
increased alloimmunisation rates in patients with systemic
viral infections. Murine experiments showed similar effects
for poly(I:C) (Hendrickson et al, 2006, 2007, 2008; Smith
et al, 2012), a synthetic viral RNA analogue that agonizes
Toll-like receptor (TLR) 3 (Alexopoulou et al, 2001). These
poly(I:C) effects were attributed to an increased dendritic cell
consumption of transfused cells with upregulation of costim-
ulatory molecules, and activation and proliferation of naive
CD4+ antigen-specific T-cells (Hendrickson et al, 2007,
2008). An existing molecular mimicry between certain viral
peptides and CD4+ T-cell red cell antigen epitopes was also
Table V. Specificity and frequency of first-formed red cell alloantibodies according to the presence of various types of infections.
Alloantibody
specificity
All patients,
N (%)
No infection,
N (%)
Severe bacterial
infection, N (%)
Viral infection
(local and
disseminated), N (%)
Gram-negative
bacteraemia, N (%)
anti-C 23 (40) 19 (52) 1 (09) 0 (0) 1 (71)
anti-c 41 (72) 25 (68) 8 (71) 0 (0) 1 (71)
anti-E 185 (323) 113 (307) 41 (364) 4 (267) 5 (357)
anti-e 5 (09) 5 (14) 0 (0) 0 (0) 0 (0)
anti-K 126 (220) 88 (239) 21 (186) 3 (200) 6 (429)
anti-Cw 19 (33) 10 (27) 4 (35) 3 (200) 0 (0)
anti-Fya 31 (54) 24 (65) 4 (35) 1 (67) 0 (0)
anti-Fyb 5 (09) 4 (11) 1 (09) 0 (0) 0 (0)
anti-Jka 54 (94) 37 (101) 8 (71) 3 (200) 0 (0)
anti-Jkb 7 (12) 4 (11) 2 (18) 0 (0) 0 (0)
anti-Lea 7 (12) 2 (05) 4 (35) 0 (0) 0 (0)
anti-Leb 3 (05) 1 (03) 1 (09) 0 (0) 0 (0)
anti-Lua 32 (56) 19 (52) 9 (80) 0 (0) 0 (0)
anti-Lub 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
anti-M 22 (38) 14 (38) 5 (44) 1 (67) 0 (0)
anti-N 1 (02) 0 (0) 0 (0) 0 (0) 0 (0)
anti-S 12 (21) 7 (19) 4 (35) 0 (0) 1 (71)
anti-s 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
(possibly) natural occurring* 268 (467) 159 (432) 64 (566) 8 (533) 5 (357)
All antibodies 573 368 113 15 14
Number of patients 505 325 100 10 13
*Including: anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M. No difference in distribution of (possibly) natural occurring alloantibodies
was observed between patients with and without severe bacterial infections (P = 008), disseminated viral infections (P = 093), and Gram-nega-
tive bacteraemia (P = 041).
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suggested, although observed effects in polyomavirus infected
mice did not reach statistical significance (Hudson et al,
2010).
Although we did not analyse the association between
latent viral infections and red cell alloimmunisation, these
might also be relevant. In addition, the assessment of possi-
ble different effects of RNA and DNA viruses was prevented
by low event numbers.
Third, we observed a twofold alloimmunisation incidence
reduction during Gram-negative bacteraemia. Analogous to
viral infections, these findings require confirmatory research.
Yet, they again corroborate animal experiments showing sig-
nificantly attenuated alloimmunisation responses upon
lipopolysaccharide (LPS) pretreatment in mice (Hendrickson
et al, 2008). LPS, an endotoxin in the outer cell membrane of
Gram-negative bacteria, strongly stimulates innate immunity
by agonizing TLR4 on macrophages and dendritic cells. Con-
versely, LPS is also implicated in a transient, possibly self-pro-
tective immune paralysis, known as LPS tolerance (Lauw et al,
2000; Weijer et al, 2002; Gould et al, 2004). Restimulation
with LPS in this respect initiates blockage of CD4+ T cell func-
tioning via impaired release of tumour necrosis factor a, inter-
leukin (IL)12 and IL18 from monocytes and dendritic cells,
together with a diminished upregulation of major histocom-
patibility complex class-II and costimulatory molecules (Mat-
tern et al, 1998; Gould et al, 2004). While regulatory T cells
selectively express TLRs (including TLR4), their LPS-induced
proliferation might also contribute to the observed effects in
both mice and humans (Caramalho et al, 2003). Finally, we
cannot exclude an indirect role for Gram-negative bacteraemia
on red cell alloimmunisation due to their common association
with other modulators. Indeed, suppressed mitogenic B and T
lymphocyte responses were observed following administration
of antibiotics, including cephalosporins, an antibiotic class fre-
quently used in the treatment of Gram-negative bacterial infec-
tions (Borowski et al, 1985; Pomorska-Mol et al, 2015).
In an intriguing contrast to the effects observed for Gram-
negative bacteraemia, we did not observe any association
between Gram-positive bacteraemia and red cell alloimmuni-
sation. A common lower degree of acute inflammation
evoked by gram-positive as compared to gram-negative
bloodstream infections due to differing virulence mechanisms
forms one hypothetical explanation (Wang et al, 2003; Gould
et al, 2004; Abe et al, 2010).
Despite the RRs for fungal infections not differing signifi-
cantly from those for Gram-negative bacteraemia, the hetero-
geneous RRs for individual fungal microorganisms and the
lack of other supportive evidence prevent tentative infer-
ences. Indeed, in contrast to our estimated RR, one report
suggested neonatal alloimmunisation to be related to a dis-
seminated histoplasmosis infection (Hata et al, 2013).
The ultimate goal of our study would be to establish an
accurate alloimmunisation prediction model, serving as a
practical tool for risk-based extended matching. Such a
model would be most feasible when based on routinely
measured patient parameters. In this perspective, we did not
observe any association of the level of leucocytosis and CRP
with alloimmunisation, possibly due to the multifactorial
nature of these parameters. Other biomarkers, e.g. cytokine
levels and immune cell subsets, might be better discrimina-
tive; however, they could not be evaluated in the current
study.
Our study design, results and interpretations require addi-
tional remarks:
First, our incidence-density sampling strategy guarantees
that selected controls were similarly exposed as their matched
cases (Rothman, 2007). Hereby, our RRs are not influenced
by transfusion burden, being a main determinant of red cell
alloimmunisation (Zalpuri et al, 2012b; Evers et al, 2016).
Second, by identifying the implicated transfusion, we could
study conditions present at that given time. As the duration of
alloimmunisation modulation is currently unknown and will
also probably differ per risk factor, we chose a seemingly large
risk period to precede the implicated transfusion. Although
one could argue that this strategy could possibly dilute some
effects, on the other hand, it assures inclusion of most factors
of influence at the time of exposure. For example, repeated
LPS exposure might induce a state of tolerance persisting for
up to 30 days (Cross, 2002). In addition, a recent study
showed that poly(I:C) facilitates red cell alloimmunisation for
at least 14 days with its maximum effect reached 7 days after
administration (Elayeb et al, 2016). As a validation of our cho-
sen risk period length, a sensitivity analysis on infections diag-
nosed during the week preceding or following the implicated
transfusion did not change our conclusions (data not shown).
Similarly, only the duration of fever accompanying severe bac-
terial infections, rather than its timing in the risk period,
affected alloimmunisation. As we aimed to target the most
likely first initiation of an alloimmune response, we limited the
risk period to the first 7 days following the implicated
transfusion.
Third, actual lag periods per antigen-specific antibody are
currently unknown. As such, our chosen lag period of 7 days
might not completely have prevented the exclusion of
patients demonstrating recall responses, including women
immunised due to prior pregnancies. Direct antiglobulin tests
were not performed on a routine basis shortly following
transfusion and as such were of no help in identifying these
patients. However, as non-RhD alloantibodies form in only
033% of first trimester pregnancies (Koelewijn et al, 2008),
we believe that a substantial influence of previous
pregnancies is unlikely. Moreover, erroneously considering a
substantial amount of boosting reactions as primary alloim-
munisation events would have biased our RRs towards the
null-effect. Indeed, a sensitivity analysis in which we
excluded the 53 patients in whom alloantibodies were discov-
ered during the second week following their first antigen-
incompatible transfusion did not substantially change RRs
(data not shown). In conclusion, we believe the eventual bias
due to our choice of the lag period to be small.
D. Evers et al
964 ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 175, 956–966
Fourth, to avoid invalid inferences due to misclassifica-
tion, we did not define patients with a non-established aeti-
ology of their inflammatory phenotype as exposed patients.
For example, for a vascular compromised patient diagnosed
with osteomyelitis, wound cultures positive for Staphylococcus
Aureus might have represented normal skin flora coloniza-
tion of a primary ischaemic wound. Consequently, the analy-
sis on severe bacterial infections did not include this patient.
A sensitivity analysis confirmed our results not to be affected
by this possible misclassification bias.
In conclusion, our data suggest a potential risk modifying
influence of infection-associated inflammation on red cell
alloimmunisation in transfused patients. Alloimmunisation
seems to be induced by severe bacterial or viral infections,
but might be skewed towards protection in the presence of
Gram-negative bacteraemia. Further confirmatory research is
needed to ultimately identify the high-risk patient and, con-
sequently, better target the allocation of more extensively
matched red cell units.
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